跳转至内容
Merck
CN

W6837

Fumaric acid-1,4-13C2

API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP)

登录查看公司和协议定价

关于此项目

线性分子式:
HOO13CCH=CH13COOH
分子量:
118.06
MDL编号:
MFCD19704797
UNSPSC代码:
12352115

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

cGMP

同位素纯度

≥99 atom % 13C

方案

≥98% (CP)

mp

298-300 (subl) (lit.)

质量偏移

M+2

储存温度

15-25°C

SMILES字符串

O[13C](/C=C/[13C](O)=O)=O

InChI

1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+/i3+1,4+1

InChI key

VZCYOOQTPOCHFL-ZWWDXPBASA-N

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

- High-resolution NMR spectroscopy
- Metabolomic profiling and pathway analysis
- Stable Isotope probing in Environmental microbiology
- Acid-catalyzed reaction mechanism studies

特点和优势

Features
  • Exceptional stability and compatibility with various ingredients.
  • High purity of Fumaric acid-1,4-13C2 API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP) ensures optimal performance.
  • Versatile use in different formulations involving Fumaric acid-1,4-13C2 API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP).
  • Cost-effective solution for Fumaric acid-1,4-13C2 API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP) applications.


Benefits
  • Reduces time to market for products utilizing Fumaric acid-1,4-13C2 API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP).
  • Increases market competitiveness of products containing Fumaric acid-1,4-13C2 API for Clinical Studies, ≥99 atom % 13C, ≥98% (CP).
  • Improves overall product quality and consumer satisfaction.
  • Enhances product efficacy and reliability in formulations.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H319,H412

危险分类

Aquatic Chronic 3 - Eye Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 1

闪点(°F)

446.0 °F - closed cup

闪点(°C)

230 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持